Oppenheimer Weighs in on Organogenesis Holdings Inc.’s FY2023 Earnings (NASDAQ:ORGO)

Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating) – Research analysts at Oppenheimer dropped their FY2023 earnings per share estimates for shares of Organogenesis in a research report issued on Thursday, November 10th. Oppenheimer analyst S. Lichtman now anticipates that the company will post earnings per share of $0.22 for the year, down from their prior estimate of $0.27. Oppenheimer has a “Market Perform” rating on the stock. The consensus estimate for Organogenesis’ current full-year earnings is $0.13 per share.

Separately, BTIG Research lowered Organogenesis from a “buy” rating to a “neutral” rating in a report on Thursday.

Organogenesis Stock Up 9.5 %

NASDAQ ORGO opened at $2.88 on Monday. Organogenesis has a 52 week low of $2.23 and a 52 week high of $11.37. The company has a quick ratio of 2.36, a current ratio of 2.62 and a debt-to-equity ratio of 0.27. The business’s fifty day simple moving average is $3.29 and its 200-day simple moving average is $4.60. The firm has a market cap of $377.04 million, a PE ratio of 6.26 and a beta of 1.73.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its position in shares of Organogenesis by 80.1% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after purchasing an additional 2,396 shares during the last quarter. KBC Group NV acquired a new stake in shares of Organogenesis during the 2nd quarter worth about $27,000. Point72 Hong Kong Ltd increased its position in shares of Organogenesis by 245.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock worth $29,000 after purchasing an additional 4,275 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of Organogenesis by 3,808.2% during the 1st quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock worth $69,000 after purchasing an additional 8,873 shares during the last quarter. Finally, Stoneridge Investment Partners LLC acquired a new stake in shares of Organogenesis during the 3rd quarter worth about $33,000. Hedge funds and other institutional investors own 44.55% of the company’s stock.

About Organogenesis

(Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Featured Articles

Earnings History and Estimates for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.